Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

Home

/

HRTX

H

Heron Therapeutics, Inc. (HRTX)

NCM – Цена в реальном времени. Валюта: USD

0.43

+0.02 (4.88%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

0.44

+0.01 (1.74%)

После закрытия: Jun 26, 2026, 7:47 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

U.S. District Court Issues Decision Regarding CINVANTI® Patents

U.S. District Court Issues Decision Regarding CINVANTI® Patents

CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid.

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics Q1 Earnings Call Highlights

Heron Therapeutics Q1 Earnings Call Highlights

Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter.

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates.

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Видео

No Data

There is no data to display

Пресс-релизы

U.S. District Court Issues Decision Regarding CINVANTI® Patents

U.S. District Court Issues Decision Regarding CINVANTI® Patents

CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid.

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates.

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

– ZYNRELEF ® and APONVIE ® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise – Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates.

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®,” said Craig Collard, Chief Executive Officer of Heron.